NFJ Investment Group LLC bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 71,489 shares of the biotechnology company's stock, valued at approximately $5,054,000.
A number of other large investors also recently made changes to their positions in BMRN. Dodge & Cox grew its stake in shares of BioMarin Pharmaceutical by 1.4% in the 1st quarter. Dodge & Cox now owns 14,955,240 shares of the biotechnology company's stock valued at $1,057,186,000 after buying an additional 209,005 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of BioMarin Pharmaceutical by 127.9% in the 1st quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company's stock valued at $203,987,000 after buying an additional 1,642,206 shares in the last quarter. Nuveen LLC bought a new stake in BioMarin Pharmaceutical during the first quarter worth approximately $184,475,000. Charles Schwab Investment Management Inc. boosted its position in BioMarin Pharmaceutical by 7.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,532,314 shares of the biotechnology company's stock worth $108,319,000 after purchasing an additional 108,806 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in BioMarin Pharmaceutical by 19.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,055,087 shares of the biotechnology company's stock worth $69,351,000 after purchasing an additional 174,634 shares during the period. Institutional investors and hedge funds own 98.71% of the company's stock.
BioMarin Pharmaceutical Trading Up 1.5%
Shares of BioMarin Pharmaceutical stock traded up $0.83 during trading on Thursday, hitting $55.33. 608,900 shares of the company were exchanged, compared to its average volume of 1,912,812. BioMarin Pharmaceutical Inc. has a 1-year low of $52.93 and a 1-year high of $85.00. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.56 and a quick ratio of 3.60. The firm has a market capitalization of $10.62 billion, a P/E ratio of 16.40, a price-to-earnings-growth ratio of 0.71 and a beta of 0.35. The firm's fifty day moving average price is $58.11 and its 200 day moving average price is $60.71.
Wall Street Analysts Forecast Growth
BMRN has been the subject of a number of recent analyst reports. HC Wainwright initiated coverage on BioMarin Pharmaceutical in a research report on Monday. They set a "neutral" rating and a $60.00 target price for the company. Wall Street Zen cut BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. Wolfe Research set a $95.00 target price on BioMarin Pharmaceutical and gave the stock an "outperform" rating in a research report on Tuesday, July 15th. Raymond James Financial assumed coverage on BioMarin Pharmaceutical in a report on Wednesday, September 3rd. They set an "outperform" rating and a $85.00 price target for the company. Finally, Zacks Research lowered BioMarin Pharmaceutical from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Eighteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $92.04.
Check Out Our Latest Stock Report on BMRN
BioMarin Pharmaceutical Profile
(
Free Report)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Recommended Stories
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
